Compare BIO-TECHNE Corp (TECH) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs VanEck Vietnam ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while VanEck Vietnam ETF trades at $16.92. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while VanEck Vietnam ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VNM | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.12 | $19.80 |
52-Week Low | $43.31 | $15.35 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNM trades at $16.84, down 2.88% on the day, reflecting bearish technical signals with moving averages indicating a downtrend. The stock lacks disclosed valuation ratios, and recent news highlights underperformance relative to other emerging markets. Key support and resistance are tightly clustered around $17, suggesting a critical price zone.
The outlook remains cautious due to technical weakness and emerging market headwinds. Investment opportunities hinge on Vietnam's economic reclassification potential, but risks include power grid strains and geopolitical tensions. Analyst sentiment is mixed, with oscillators showing some bullish divergence amid broader bearish indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
